Gorham-Stout Disease Successfully Treated With Sirolimus and Zoledronic Acid Therapy
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Jan 2016 · 1 min read
In brief
In brief
An 18-year-old male with Gorham-Stout disease presenting with lytic rib lesions and refractory pleural effusion achieved dramatic response using combination sirolimus (mTOR inhibitor) and zoledronic acid after interferon failure. This well-tolerated dual-agent approach shows promise for treating this rare life-threatening disorder characterized by lymphatic malformation and progressive bone destruction.
Written by the GCMD Library team from the article.
Statements in this article
Gorham-Stout disease is a life-threatening disorder often manifested by lymphatic malformation and osteolysis.
Available therapies for Gorham-Stout disease are not uniformly effective and often carry substantial morbidity.
An 18-year-old male with Gorham-Stout disease manifested by lytic rib lesions and intractable pleural effusion responded dramatically to combination therapy with sirolimus and zoledronic acid after failing interferon therapy.
The combination of sirolimus and zoledronic acid has demonstrated synergism in preclinical cancer models.